Dr. Ghebeh is interested in cancer immunotherapy, especially the immunobiology of immune checkpoints and their signaling pathways. His group focus on the intrinsic role of immune checkpoints like PD-L1 on cancer cell carcinogenesis. They aim to improve cancer therapy by developing a better combination of an immune checkpoint inhibitor with another type of therapy like chemotherapy, targeted therapy, or a food supplement. Additionally, they are interested in Identifying biomarkers for patients likely to benefit from therapy.